

# CURRICULUM VITAE

## Morton S Kahlenberg, MD, FACS

### GENERAL INFORMATION

#### PERSONAL DATA:

Date of Preparation: 07/21/2008

**Address:** 8711 Village Drive  
San Antonio, TX 78217

**Phone Number:** (210) 946-1400

**Fax Number:** (210) 946-1010

**Email Address:** KAHLENBERG@SurgOncSouthTexas.com

#### POSITIONS AND APPOINTMENTS:

- Medical Director, Surgical Oncology Associates of South Texas
- Director, Baptist Cancer Center, Baptist Health Systems, San Antonio, Texas

#### EDUCATION:

<u>Year</u>	<u>Degree</u>	<u>Discipline</u>	<u>Institution/Location</u>
1990	MD	Medicine	McGill University, Montreal, Quebec, Canada
1986	BCS	Chemical Science	McGill University, Montreal, Quebec, Canada
1985	Diploma of Collegial Studies	Health Science	Marianopolis College of Quebec, Canada, Quebec, Canada

#### TRAINING:

##### *Internship*

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1990-1991	General Surgery	University of North Carolina, Chapel Hill, NC

##### *Post Doctoral Fellowship*

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1997-1999	Surgical Oncology	Roswell Park Cancer Institute State University of New York, Buffalo, NY
1995-1997	Research NIH T-32	Roswell Park Cancer Institute State University of New York, Buffalo, NY

York, Buffalo, NY

**Residency**

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1991-1995	General Surgery	University of North Carolina, Chapel Hill, NC

**ACADEMIC APPOINTMENTS:**

05/2008 - Present	Clinical Associate Professor	University of Texas Health Science Center at San Antonio,
09/2006 – 04/2008	Associate Professor with Tenure	University of Texas Health Science Center at San Antonio, Department of Surgery, San Antonio, TX
08/2006 – 04/2008	Chief of Staff	The Cancer Therapy and Research Center, San Antonio, TX
08/2005 – 04/2008	Interim Director, Center for Clinical Oncology	University of Texas Health Science Center at San Antonio, TX
08/2005 – 04/2008	Associate Director for Clinical Affairs	San Antonio Cancer Institute, San Antonio, TX
09/2003 – 08/2006	Associate Professor	University of Texas Health Science Center at San Antonio, Department of Surgery, San Antonio, TX
08/2002 – 04/2008	Chief, Division of Surgical Oncology	University of Texas Health Science Center at San Antonio, TX
07/1999 - 08/2003	Assistant Professor	University of Texas Health Science Center at San Antonio, Department of Surgery, San Antonio, TX
07/1995 - 07/1999	Instructor	State University of New York, Buffalo, NY

**NON-ACADEMIC APPOINTMENTS:**

None- Present	Institutional Surgical Principal Investigator	University of Texas Health Science Center, San Antonio, TX
---------------	---	--

**CERTIFICATION AND LICENSURE:**

***Board Certification***

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Expiration</u>
Surgery - American Board of Surgery	Certified	10/1996	07/2017

***License to Practice***

<u>Description/Agency</u>	<u>Status</u>	<u>Date</u>	<u>Expiration</u>
---------------------------	---------------	-------------	-------------------

Medicine - Texas State Board of Medical Examiners	Certified	<u>Acquired</u> 02/2000	02/2009
---	-----------	----------------------------	---------

**HONORS AND AWARDS:**

12/2006 Global Directory of Who's Who

11/2006 San Antonio's Top Doctors, Scene in San Antonio Monthly

03/2006 San Antonio's Best Doctors, San Antonio Magazine

02/2006 San Antonio's Best Doctors, San Antonio Monthly

12/2005 San Antonio's Best Doctors, Scene in San Antonio Monthly

02/2005 The Society of University Surgeons: Elected to limited membership (250 members worldwide). Represents recognized academic achievement in surgery.

12/2002 40 Under 40 Award, San Antonio's Rising Stars Award

04/2002 Presidential Clinical Faculty Award, Nominee

01/2002 Member of National Colorectal Cancer Working Group: NSABP

10/2001 American College of Surgeons: Faculty Research Grant

01/2001 Principal Investigator: University of Texas Health Science Center, NSABP

01/2001 National Gastrointestinal Cancer Committee (Southwest Oncology Group)

03/2000 Howard Hughes Medical Institute: Research Grant

06/1999 Rhone-Poulenc Rorer: Surgical Oncology Fellows Scholarship

06/1999 E. D. Holyoke Award: Fellow of the Year, Roswell Park Cancer Institute

06/1999 Clinical Research Paper of the Year: Roswell Park Cancer Institute

11/1998 Berlex Oncology Foundation: Epidemiology and Clinical Trials Workshop

09/1998 Chief Administrative Fellow: Division of Surgical Oncology, Roswell Park

08/1998 Poster of Distinction: Society for Surgery of the Alimentary Tract

02/1997 Berlex Oncology Foundation: Molecular Biology Workshop

04/1996 American College of Surgeons: Research Award, Western N.Y. Chapter

06/1995 James Ewing Travel Scholarship: Oncologic Research

02/1995 NIH T32 Training Grant: Oncology Basic Science Research

10/1989 Prix D'Excellence for Research: Government of Quebec

09/1989 Fonds de la Recherche et Sante du Quebec: Research Scholarship

04/1988 FRSQ: Research Scholarship

05/1987 Farquharson Research Scholarship: Medical Research Council of Canada

06/1984 Sister Mary MacCormac Scholarship: Academic Excellence

**PROFESSIONAL DEVELOPMENT:**

***Administrative***

<b><u>Date</u></b>	<b><u>Description</u></b>	<b><u>C.E.</u> <u>Units/Hours</u></b>
01/20/2006 - 06/02/2006	Mini-MBA Program, The University of Texas Health Science Center at San Antonio. Leadership and Administrative Program.	0.00 / 60.00

**TEACHING**

**COURSE BASED TEACHING:**

<b><u>Date</u></b>	<b><u>Course Name</u></b>	<b><u>Level</u></b>	<b><u>Role</u></b>
05/2004 - Present	SURG4002 Surgical Oncology	Undergraduate	Team Teacher
	<i>Surgical Oncology Elective - MS</i>		
07/2000 - 08/2001	SURG7001 Special Topic	Undergraduate	Team Teacher
	<i>Clinical Integration Course - MS/P</i>		
09/1999 - Present	SURG4003 Surgical Anatomy	Undergraduate	Lecturer
	<i>Breast Anatomy Year 1 - MS/P Breast and Chest</i>		
09/1999 - Present	SURG7001 Special Topic	Undergraduate	Lecturer
	<i>General Surgery Core Curriculum Breast Cancer - MS/P</i>		

## **OTHER TEACHING:**

### ***Group Instruction***

<b><u>Date</u></b>	<b><u>Description</u></b>	<b><u>Institution</u></b>	<b><u># Students</u></b>
09/2004 - Present	Medical Gross Anatomy and Embryology <i>Annual class for first year medical students</i>	UTHSCSA	206
09/1999 - Present	Ward Instructor <i>Ward Instructor, MS/P (Approximately 12 students per 3-month rotation)</i>	UTHSCSA	12
09/1999 - Present	Clinic Instructor <i>Clinic Instructor - MS/P, R (Approximately 12 students per 3-month rotation)</i>	UTHSCSA	12
09/1999 - Present	Operating Room <i>Operating Room, MS/P, R (Approximately 12 students per 3-month rotation)</i>	UTHSCSA	12
09/1999 - Present	Endoscopy Center <i>Endoscopy Center, MS/R (Approximately 12 students per 3-month rotation)</i>	UTHSCSA	12

## **RESEARCH**

### **EXPERTISE:**

**Colon Cancer** - The Effects of Silibinin in Colon and Rectal Cancer.

**Colon and Rectal Cancer** - The Effects of Eugenol in Colon and Rectal Cancer

**Colorectal Cancer** - Receptor Tyrosine Kinase Signal Transduction in Colorectal Cancer.

**Colorectal Cancer** - Mismatch Repair Gene Defects in Young Hispanic Patients with Colorectal Cancer.

**Colorectal Cancer** - The Effects of Silibinin in Colorectal Cancer

**NSAID** - Effects of NSAID Administration on Endonuclease Expression and Genomic Instability

**Pancreatic Growth Factor** - Effects of a New Pancreatic Growth Factor on the Exocrine Pancreas.

**Pancreatic Growth Factor** - Physiochemical Characterization of a Novel Pancreatic Growth Factor.

**Rectal Cancer** - Ras Oncogene Mutations in Rectal Cancer as an Indicator of Minimal Residual Disease.

**Sporadic Colorectal Cancer** - Endonuclease Expression and Genomic Instability in Sporadic Colorectal Cancer.

**Sporadic Colorectal Cancer** - p53 Tumor Suppressor Gene and Genomic Instability in Sporadic Colorectal Cancer.

**Sporadic Colorectal Carcinogenesis** - Modifier of MIN-APC (MOM) and its Role in Sporadic Colorectal Carcinogenesis.

## **PROJECTS:**

### ***Clinical Trials***

07/2005- ACOSOG Z9031, A Phase III Randomized Study of Preoperative Radiation Plus Surgery  
03/2006 Versus Surgery Alone for Patients with Retroperitoneal Sarcoma

01/2001- National Surgical Adjuvant Breast and Bowel Project, Institutional Principal Investigator:  
Present

NSABP B-04: A Protocol for the Evaluation of Radical Mastectomy and Total Mastectomy With and Without Radiation in the Primary Treatment of Cancer of the Female Breast.

NSABP B-06: A Protocol to Compare Segmental Mastectomy and Axillary Dissection With and Without Radiation of the Breast and Total Mastectomy and Axillary Dissection.

NSABP B-09: A Clinical Trial to Compare Combination Chemotherapy With and Without Tamoxifen in the Management of Patients with Surgically "Curable" Breast Cancer Who Have One or More Positive Axillary Nodes.

NSABP B-12: A Clinical Trial to Compare PFT With and Without Adriamycin in the Management of Patients With Primary Breast Cancer and Positive Axillary Nodes Whose Tumors are Positive for Estrogen Receptors and/or Positive Progesterone Receptors.

NSABP B-13: A Clinical Trial to Assess Sequential Methotrexate - 5-Fluorouracil in Patients With Primary Breast Cancer and Negative Axillary Nodes Whose Tumors Are Negative for Estrogen Receptors.

NSABP B-14: A Clinical Trial to Assess Tamoxifen in Patients With Primary Breast Cancer and Negative Nodes Whose Tumors are Positive for Estrogen Receptors.

NSABP B-15: A Three Arm Clinical Trial Comparing Short Intensive Adriamycin-Cyclophosphamide Chemotherapy With and Without Interval Reinduction Chemotherapy (CMF) to "Conventional" CMF in positive Node Patients.

NSABP B-16: A Three Arm Clinical Trial Comparing Tamoxifen Alone With L-PAM, 5-FU and Tamoxifen or With Short Intensive Adriamycin-Cyclophosphamide and Tamoxifen in Positive Node Patients.

NSABP B-17: A Clinical Trial to Evaluate Natural History and Treatment of Patients With Non-Invasive Intraductal Adenocarcinoma and Lobular In Situ Registry.

NSABP B-18: A "Unified" Trial to Compare Short Intensive Pre-Operative Systemic Adriamycin Cyclophosphamide Therapy With Similar Therapy Administered in Conventional Post-Operative Fashion.

NSABP B-19: A Clinical Trial to Compare Sequential Methotrexate 5-FU (M-F) With Conventional CMF in Primary Breast Cancer Patients With Negative Nodes and Estrogen Receptor Negative Tumors.

NSABP B-20: A Clinical Trial to Determine the Worth of Chemotherapy and Tamoxifen Over Tamoxifen Alone in the Management of Patients With Primary Invasive Breast Cancer, Negative Axillary Nodes and Estrogen Receptor Positive Tumor.

NSABP B-21: A Clinical Trial to Determine the Worth of Tamoxifen and the Worth of Breast Radiation in the Management of Patients With Node-Negative, Clinically Occult, Invasive Breast Cancer Treated by Lumpectomy.

NSABP B-22: A Clinical Trial to Evaluate the Effect of Dose Intensification and Increased Cumulative Dose of Postoperative Adriamycin-Cyclophosphamide (AC) Therapy on the Disease-Free Survival and Survival of Patients With Primary Breast Cancer and Positive Axillary Nodes.

NSABP B-23: A Clinical Trial Comparing Short, Intensive AC + Tamoxifen With Conventional CMF + Tamoxifen in Node-Negative Breast Cancer Patients With ER-Negative Tumors.

NSABP B-24: A Clinical Trial to Evaluate the Worth of Tamoxifen in Conjunction With Lumpectomy and Breast Irradiation for the Treatment of Noninvasive Intraductal Carcinoma (DCIS) of the Breast.

NSABP B-25: A Clinical Trial to Evaluate the Effect of Dose Intensification and Increased Cumulative Dose of Adriamycin-Cyclophosphamide (AC) Therapy With G-CSF on the Disease-Free Survival and Survival of Patients With Primary Breast Cancer and Positive Axillary Nodes.

NSABP B-26: A Randomized Trial of Patients With Metastatic or Locally Advanced Breast Cancer Comparing the Effect of 3-Hour vs. 24-Hour Infusion of High-Dose Taxol.

NSABP B-27: A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed By Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel in Patients With Operable Carcinoma of the Breast.

NSABP B-28: A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients With Positive Axillary Nodes.

NSABP B-30: A Three-arm randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Cyclophosphamide (AC→T); Adriamycin and Taxotere

(AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes.

NSABP B-31: Subject Consent to Take Part in A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC6T) to that of Adriamycin and Cyclophosphamide followed by Taxol Plus Herceptin (AC6T + H) in Node-Positive Breast Cancer Patients who have Tumors that Overexpress HER2.

NSABP B-32: A Randomized Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node Negative Breast Cancer Patients.

NSABP B-33: A Randomized, Placebo-Controlled, Double –Blind Trial Evaluating the Effects of Exemestane in Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing at Least Five years Tamoxifen Therapy.

NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and /or No Therapy.

NSABP B-35: A Clinical Trial comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy.

NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of Fluorouracil and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), with or without Celecoxib in Patients with Node-Negative Breast Cancer.

NSABP B-37 (Version as of 12/15/2004)

A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer

NSABP B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer.

NSABP B-39 (Version as of 1/24/2005)

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

NSABP BP-57: A Phase II Study in Patients with Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Doxorubicin (Adriamycin) and Docetaxel (Taxotere) (AT).

NSABP C-03: A Clinical Trial to Compare Adjuvant Leucovorin and 5-FU (LV-5-FU) With Adjuvant Meccnu, Vincristine And 5-FU In Patients With Duke's B and C Carcinoma of the Colon.

NSABP C-04: A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon.

NSABP C-05: A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin With or Without Interferon Alfa-2a in Patients With Dukes' B & C Carcinoma of the Colon.

NSABP C-06: A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) plus LV in the Treatment of Patients With Stages II and III Carcinoma of the Colon.

NSABP C-07: A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU Plus Leucovorin for the Treatment of Patients with Stages II and III Carcinoma of the Colon.

NSABP C-08: A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon.

NSABP P-1: A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer.

NSABP P-2: The Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer.

NSABP R-02

A Clinical Trial to Compare Adjuvant Methyl CCNU, Vincristine, 5-FU (MOF) With and Without Radiation to Adjuvant Leucovorin and 5-FU ((LV-5FU) With and Without Radiation in Patients With Duke's B and C Carcinoma of the Rectum.

NSABP R-03: A Clinical Trial to Evaluate the Worth of Preoperative Multimodality Therapy (5FU-LV and RTX) in Patients with Operable Carcinoma of the Rectum.

NSABP R-04

A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

07/2000- Present SWOG, Southwest Oncology Group - Institutional Surgical Principal Investigator

### ***Collaborative Research***

06/2006- Present The Effects of Eugenol in Melanoma

01/2005-06/2005 Study of molecular requirements to transform normal tissue to cancer, Oncogenic effects in human mammary and colorectal epithelial cells transplanted into mice.

01/2003- Present Colorectal Cancer, Mismatch Repair Gene Defects in Young Hispanic Patients with Colorectal Cancer.

01/2000- Present Colorectal Cancer, Colorectal Cancer in Hispanics

### ***Pilot Research***

08/2006- Present The Effects of Eugenol in Colon and Rectal Cancer

- 07/2005- Present The Effects of Silibinin and Silymarin in Colon and Rectal Cancer
- 01/2001-12/2001 Treatment of Breast Cancer, The prognostic significance of molecular markers in the neoadjuvant treatment of breast cancer.
- 01/1999- Present Colorectal Cancer, Receptor tyrosine kinase signal transduction in colorectal cancer.

### **University Projects**

- 01/1999- Present Colorectal Cancer Screening Program, Development of University-based colorectal cancer screening program.

### **PUBLICATIONS: (\* indicates Peer Reviewed)**

#### **Abstract**

- \* 1. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, Silibinin, Inhibits Proliferation and Promotes Cell-cycle Arrest of Human Colon Cancer. 2007 Mar. (Society of Surgical Oncology 60th Annual Cancer Symposium, Washington DC).
- \* 2. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Silibinin inhibits proliferation of human colon cancer. Phoenix, AZ: 2007 Feb. (2nd Academic Surgical Congress).
- \* 3. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavanoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer cell lines: Fet, Geo, HCT116. San Antonio, TX: 2006 Jun. (Presented at the 32nd Annual Meeting of the J. Bradley Aust Society).
- \* 4. Learn PA, Krishnegowda N, Talamantez J, Kahlenberg MS. Selective EGFR Tyrosine Kinase Inhibition Increases HER-2/neu Expression and Activation in Colon Cancer Cell Lines. 2006 Mar. (The Society of Surgical Oncology Cancer Symposium).
- 5. Wang HT, Barone CM, Kahlenberg MS, Berger J, Daum A, Ortegon D. Aesthetic Outcomes in Breast Conservation Therapy 2006. (American Society of Plastic Surgery).
- \* 6. Jill Uecker, P Learn, Kahlenberg MS, S Hamilton, Jagirdar J. High Frequency of DNA Mismatch Repair Gene Defects in Colorectal Cancer (CRC) of Hispanic Patients Texas Society of Pathology.
- \* 7. Zubyk S, Fuller CD, Kahlenberg MS, Miller AR, Patnaik A. Altered fractionation chemoradiotherapy for locally advanced rectal cancer. Proceedings of the 2004 Gastrointestinal Cancers Symposium. 2004 Jan. p. 139. (American Society of Clinical Oncology).
- \* 8. Kahlenberg MS, Stefanidis D, Miranda J, Wong A, Pollock B, Thomas Jr C, Rousseau

Jr. D. Colorectal Cancer in Hispanics: A population at risk for earlier onset, advanced disease and decreased survival. Proceedings of the 2004 Gastrointestinal Cancers Symposium. 2004 Jan. p. 177. (American Society of Clinical Oncology).

- \* 9. Kahlenberg MS, Talamantez J, Brattain M. Compensatory increases in Her-2-Neu expression and activation in response to epidermal growth factor receptor inhibition in colorectal cancer. Proceedings of the 2004 Gastrointestinal Cancers Symposium 2004 Jan. p. 161. (American Society of Clinical Oncology).
- \* 10. Stefanidis D, Miranda J, Wong A, Pollock B, Thomas Jr C, Kahlenberg MS. Colorectal cancer in Hispanics: A population at risk for earlier onset, advanced disease and decreased survival. Proceedings of the Society of Surgical Oncology 2004. (Annals of Surgical Oncology; vol. 11, no. 02).
- \* 11. Stefanidis D, Brown K, Nazario HE, Trevino-Alanis H, Ferral H, Brady III CE, Gross GW, Postoak DW, Chadhury R, Kahlenberg MS. Safety and Efficacy of Metallic Stents in the Management of Colorectal Obstruction. Proceedings of the Society of Surgical Oncology 2004. p. S113. (Annals of Surgical Oncology; vol. 11, no. 2).
- \* 12. Bear HD, Anderson S, Smith RE, Robidoux A, Kahlenberg MS, Margolese RG, Dakhil SR, Pajon ER, Hoehn JL, Mamounas EP, Geyer CE, Julian TB, Wolmark N. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP 2004. p. S16. (Breast Cancer Research and Treatment; vol. 88, no. 1).
- 13. Stefanidis D, Miranda J, Wong A, Thomas CR, Rousseau DL, Pollock BH, Kahlenberg MS. Colorectal cancer in Hispanics: A population at risk for earlier onset, advanced disease and decreased survival 2004. (Ann Surg Oncol).
- 14. Stefanidis D, Brown K, Nazario HE, Ferral H, Postoak DW, Brady III CE, Kahlenberg MS. Safety and efficacy of metallic stents in the treatment of colorectal cancer 2004. (Ann Surg Oncol).
- \* 15. Kahlenberg MS, Talamantez J, DeBono J, Brattain MG. Receptor Tyrosine Kinase Compensation in Response to Epidermal Growth Factor Receptor Inhibition. 94th Annual Meeting of the American Association for Cancer Research 2003 Atlanta GA. Oral presentation. 2003.
- \* 16. Bovio SG, Kahlenberg MS, Miller AR, Patnaik A, Takimoto C, Hidalgo M, Eng T, Thomas Jr C. Altered fractionation with concomitant boost (CB) chemoradiotherapy for locally advanced rectal cancer. 94th Annual Mtg of the American Assoc. for Cancer Research, Abstract no. 6386.(poster pres.& AACR Minority Scholar Award in Cancer Res. to Dr. Bovio) Toronto: 2003.
- \* 17. Bovio SG, Kahlenberg MS, Miller AR, Patnaik A, Takimoto C, Thomas Jr C. Feasibility analysis of altered fractionation radiotherapy for rectal cancer: the San Antonio Cancer Institute experience. American Radium Society 85th Annual Meeting, Hotel Inter-Continental, Paris, France,(poster presentation) 2003.
- \* 18. Kahlenberg MS, Yeh I, Frome A, McNutt M, Miller AR, Sharkey FE, Cruz AB, Pollock BH. Molecular prognostic factors do not predict response to neoadjuvant chemotherapy for breast cancer. 2003. (Proc. of the Society of Surgical Oncology).

- \* 19. Bovio SG, Kahlenberg MS, Miller AR, Patnaik A, Takimoto C, Hidalgo M, Dorman J, Deegan N, Thomas Jr C. Concomitant boost radiotherapy with protracted continuous infusion 5-fluorouracil for locally advanced rectal cancer. MD Anderson Cancer Center Gastrointestinal Cancer Research Conference, Orlando, November 21-23, 2002 (oral presentation & resident trav 2002 Nov.
- \* 20. Bovio SG, Kahlenberg M, Miller AR, Patnaik A, Takimoto C, Hidalgo M, Dorman J, Deegan N, Thomas Jr C. Concomitant boost radiotherapy with protracted continuous infusion 5-fluorouracil for locally advanced rectal cancer. 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans. 2002.
- \* 21. Leyendecker JR, Kahlenberg MS, Roman J, Chopra S, Chintapalli KN et al. MR Colonography: In Vitro Assessment of Three intraluminal Contrast Agents at 5 mm, 3mm slice Thickness. 2001 Nov.
- \* 22. Jessup JM, Page C, Romero O, Gaskill H, Dorman J, Miller AR, Kahlenberg MS, Cruz Jr A. Obesity may be associated with a better outcome in breast and colorectal carcinoma. Proceedings of the Society of Surgical Oncology, Abstract # 111. 2001 Mar.
- \* 23. Thomason V, Miller AR, Alrahwan D, Kahlenberg MS. Sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Proceedings of the Society of Surgical Oncology, Abstract # 2. 2001 Mar. p. 35.
- \* 24. Miller AR, Brandao G, Prihoda T, Siragusa, Kahlenberg MS. Positive margins following surgical excision of breast carcinoma: analysis of pathologic correlates. 23 rd Annual San Antonio Breast Cancer Symposium. 2000.
- \* 25. Kahlenberg MS, Stoler DL, Rodriguez-Bigas M, Weber TW, Anderson GR, Petrelli NJ. p53 mutations are associated with decreased survival in colorectal cancer patients., Proceedings of the Society of Surgical Oncology 1999 Mar.
- \* 26. Kahlenberg MS, Volpe C, Stoler DL, Rodriguez-Bigas M, Petrelli NJ, Anderson GR. Suppression of endonuclease expression by nonsteroidal antiinflammatory drugs (NSAID's) in sporadic colorectal cancer 1998. p. A1398. (Gastroenterology; vol. 114).
- \* 27. Kahlenberg MS, Volpe C, Klippenstein D, Penetrante R, Petrelli NJ, Rodriguez-Bigas M. Clinicopathologic effects of cryotherapy on hepatic vessels and bile ducts. Proceedings of the Society of Surgical Oncology, Abstract #66. 1998. p. 65.
- \* 28. Kahlenberg M, Stoller DL, Volpe C, Petrelli NJ, Anderson GR. Nonsteroidal antiinflammatory drugs (NSAID's) reduce genomic instability in colorectal tumor cells. Proceedings of the Society of Surgical Oncology, Abstract #19. 1998. p. 53.
- \* 29. Anderson GR, Stoler DL, Kahlenberg MS, Basik M, Rodriguez-Bigas M, Petrelli NJ. Intrachromosomal genomic instability in sporadic colorectal cancer. Proceedings of the Cancer Genetics and Tumor Suppressor Genes Conference, Frederick Meeting. 1997. p. 91.
- \* 30. Kahlenberg M, Volpe C, Stoler DL, Rodriguez-Bigas M, Petrelli NJ, Anderson GR. Nonsteroidal antiinflammatory drugs (NSAID's) suppress endonuclease expression in

sporadic colorectal cancer 1997. p. 868-870.

- \* 31. Kahlenberg MS, Stoler DL, Rodriguez-Bigas M, Petrelli NJ, Anderson GR. Elevated endonuclease expression is associated with genomic instability in sporadic colorectal cancers. Proceedings of the American Association of Cancer Research, Vol 38, Abstract # 3423. 1997. p. 510.
- \* 32. Kahlenberg M, Stoler DL, Rodriguez-Bigas M, Weber TW, Petrelli NJ, Anderson GR. Modifier of Min (MOM) Does Not Play a Role in Sporadic Colorectal Carcinogenesis. Proceedings of the Society of Surgical Oncology, Abstract #40. 1997 Jan. p. 44.
- \* 33. Kahlenberg MS, Stoler DL, Rodriguez-Bigas M, Weber TW, Petrelli NJ, Anderson GR. p53 mutation is not associated with enhanced genomic instability in sporadic colorectal cancer. Proceedings of the American Association of Cancer Research, Vol. 37, Abstract #3731, page 545, 1996. 1996.
- \* 34. Kahlenberg M, Semelka B, Cance WG. Comparison of MRI with fat suppression and CT with arterial portography (CTAP) for staging of colorectal hepatic metastases. Proceedings of the Society of Surgical Oncology, Abstract #82. 1995. p. 56.

### ***Book Chapter***

1. Kahlenberg MS, Rousseau DL, Strasser J, Raser A, Petrelli N. Rectal Cancer: Management of Locoregional Disease In: Gastrointestinal Oncology: Principles and Practices, 2nd Edition. Lippincott, Williams & Wilkins; 2007.
2. Kahlenberg MS, Schwesinger WH. Colorectal Cancer in Griffith's 5 Minute Clinical Consult. In: The 5-Minute Clinical Consult. 2004.

### ***Book/Monograph***

- \* 1. Kahlenberg MS, Thomas CR. Multidisciplinary Approach to Anal Cancer. Surgical Oncology Clinics of America. WB Saunders Company, Philadelphia, PA.; 2004.

### ***Editorial***

1. Kahlenberg MS, Schwesinger W. Colorectal Cancer in Griffiths 5 Minute Clinical Consult. 2003
2. Kahlenberg MS. Surgical Management of Colorectal Cancer General Surgery News 2002

3. Kahlenberg MS. Surgical Treatment of Colorectal Cancer General Surgery News 2001 May;19-23.

### **Journal Article**

1. Rastogi P, Anderson S, Bear H, Geyer C, Kahlenberg MS, Robidoux A, Margolese R, Hoehn J, Vogel V, Dakhil S, Tamkus D, King K, Pajon E, Wright M, Robert J, Paik S, Mamounas E, Wolmark N. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 Journal of Clinical Oncology 2008 Feb;26(5):778-785.
2. Liang S, Kahlenberg MS, Rousseau DL, Hornsby P. Neoplastic conversion of human colon smooth muscle cells: No requirement for telomerase Mol Carcinog (Epub ahead of print) 2007 Dec
- \* 3. Hogan FS, Krishnegowda, NK, Mikhailova M, Kahlenberg MS. Flavanoid, Silibinin, Inhibits Proliferation and Promotes Cell-cycle Arrest of Human Colon Cancer. 2007 Nov;143(1):58-65.
- \* 4. Learn PA, Krishnegowda N, Talamantez J, Kahlenberg MS. Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. J Surg Res 2006 Dec;136(2):227-231.
- \* 5. Bear HD, Anderson S, Smith RE, Geyer C, Mamounas EP, Fisher B, Brown A, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham L, Wolmark N. Sequential preoperative or postoperative Docetaxel added to preoperative Doxorubicin plus Cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 Journal of Clinical Oncology 2006 May;24(13):2019-2027.
- \* 6. Stefanidis D, Pollock BH, Miranda J, Wong A, Sharkey FE, Rousseau DL, Thomas CR, Kahlenberg MS. Colorectal cancer in Hispanics: A population at risk for earlier onset, advanced disease, and decreased survival. Am J Clin Oncol 2006 Apr;29(2):123-126.
7. Learn PA, Krishnegowda, N, Talamantez, J, Kahlenberg MS. Compensatory increases in HER-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines Journal of Surgical Research 2006 Jan;136:227-231.
- \* 8. Stefanidis D, Pollock BH, Miranda J, Wong A, Sharkey FE, Thomas CR, Rousseau DL, Kahlenberg MS. Colorectal cancer in Hispanics: A population at risk for earlier onset, advanced disease and decreased survival Am J Clin Oncol 2006;29(2):123-126.
- \* 9. Stefanidis D, Brown K, Nazario HE, Trevino-Alanis H, Ferral H, Brady III CE, Gross GW, Postoak DW, Chadhury R, Rousseau DL, Kahlenberg MS. Safety and efficacy of metallic stents in the management of colorectal obstruction. Journal of the Society of Laparoendoscopic Surgeons 2005 Oct;9(4):454-459.
- \* 10. Rousseau DL, Thomas CR, Petrelli NJ, Kahlenberg MS. Squamous cell carcinoma of

the anal canal Surgical Oncology 2005 Sep;14(3):121-132.

- \* 11. Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL, Sharkey FE, Cruz AB, Kahlenberg MS. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast cancer. Cancer 2005 Jun;103(11):2252-2260.
- 12. Learn PA, Yeh I, McNutt, M, Chisholm, GB, Pollock BH, Rousseau DL, Sharkey FE, Cruz AB, Kahlenberg MS. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in operable breast cancer Cancer 2005 Jan;103(11):2252-2260.
- \* 13. Stefanidis D, Brown K, Nazario H, Trevino HH, Ferral H, Brady CE III, Gross GW, Postoak DW, Chaudhury R, Kahlenberg MS. Safety and efficacy of metallic stents in the management of colorectal obstruction JSL 2005;9(4):454-459.
- \* 14. Gibbs JF, Litwin AM, Kahlenberg MS. Contemporary management of benign liver tumors. Surg Clin North Am 2004 Apr;84(2):463-480.
- \* 15. Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am 2004 Apr;13(2):263-275.
- \* 16. Billingsley KG, Stern LE, Lowy AM, Kahlenberg MS, Thomas CR. Uncommon anal neoplasms. Surg Oncol Clin N Am 2004 Apr;13(2):375-388.
- \* 17. Rousseau DL, Petrelli NJ, Kahlenberg MS. Overview of anal cancer for the surgeon. Surg Oncol Clin N Am 2004 Apr;13(2):249-262.
- \* 18. Kahlenberg MS, Sullivan JM, Witmer DD, Petrelli NJ. Molecular prognostics in colorectal cancer. Surg Oncol 2003 Nov;12(3):173-186.
- \* 19. Yeh IT, Dimitrov D, Otto P, Miller AR, Kahlenberg MS, Cruz A. Pathologic review of atypical hyperplasia identified by image-guided breast needle core biopsy. Correlation with excision specimen. Arch Pathol Lab Med 2003 Jan;127(1):49-54.
- \* 20. Kahlenberg MS, Sullivan J, Witmer D, Petrelli N. Molecular prognostics in colorectal cancer Surgical Oncology 2003;12:173-186.
- \* 21. Kahlenberg MS, Kazantsev GB, Fidda N, Sharkey FE. Pseudomembranous colitis and necrosis of a malignant rectal polyp. Surgery Rounds 2002 Oct;35:495-499.
- \* 22. Kane JM, Kahlenberg MS, Rodriguez-Bigas MA, Gibbs JF, Petrelli NJ. Intraoperative hepatic lymphatic mapping in patients with liver metastases from colorectal carcinoma. Am Surg 2002 Sep;68(9):745-750.
- \* 23. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, Otto PM, McKay C, Kahlenberg MS, Phillips WT, Cruz AB. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002 Apr;9(3):243-247.
- \* 24. Anderson GR, Brenner BM, Swede H, Chen N, Henry WM, Conroy JM, Karpenko MJ, Issa JP, Bartos JD, Brunelle JK, Jahreis GP, Kahlenberg MS, Basik M, Sait S, Rodriguez-Bigas MA, Nowak NJ, Petrelli NJ, Shows TB, Stoler DL. Intrachromosomal

genomic instability in human sporadic colorectal cancer measured by genome-wide allelotyping and inter-(simple sequence repeat) PCR. Cancer Res 2001 Nov;61(22):8274-8283.

- \* 25. Kahlenberg M, Kane JM, Kanter PM, Weber TK, Gibbs JF, Rodriguez-Bigas M, Petrelli NJ. Hepatic lymphatic mapping: A pilot study for porta hepatis lymph node identification Cancer Investigation 2001;19(3)
- \* 26. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, Weber TK, Driscoll DL, Anderson GR, Petrelli NJ. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 2000 Apr;88(8):1814-1819.
- \* 27. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, Anderson GR. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A 1999 Dec;96(26):15121-15126.
- \* 28. Kahlenberg M, Stoler D, Basik M, Petrelli NJ, Rodriguez-Bigas M, Anderson GR. p53 tumor suppressor gene status and genomic instability in sporadic colorectal cancers Journal of the National Cancer Institute 1999;88:1665-1670.
- 29. Hurd TC, Proulx G, Edge SB, Schwartz G, Kahlenberg MS, Khatri V, Stomper PC, Winston JS. Treatment of Early Stage Breast Cancer. Current Problems in Cancer 1999;23(4):144-228.
- \* 30. Kahlenberg MS, Volpe C, Klippenstein DL, Penetrante RB, Petrelli NJ, Rodriguez-Bigas MA. Clinicopathologic effects of cryotherapy on hepatic vessels and bile ducts in a porcine model. Ann Surg Oncol 1998 Dec;5(8):713-718.
- \* 31. Kahlenberg MS, Stoler DL, Petrelli NJ, Rodriguez-Bigas M, Weber TK, Anderson GR. Absence of frequent involvement of modifier of Min(APC) in sporadic colorectal cancer. Ann Surg Oncol 1998 Mar;5(2):181-185.
- \* 32. Kahlenberg M, Volpe C, Stoler DL, Rodriguez-Bigas M, Petrelli NJ, Anderson GR. Nonsteroidal antiinflammatory drugs (NSAID's) suppress endonuclease expression in sporadic colorectal cancer Surgical Forum 1997;XL(VIII):868-870.
- \* 33. Stoler D, Kahlenberg MS, Basik M, Anderson GR. Inter-SSR PCR and the analysis of factors driving genomic instability in sporadic colorectal cancer 3rd Internet World Congress on Biomedical Sciences. SAA0101 1996 Dec
- \* 34. Kahlenberg MS, Stoler DL, Basik M, Petrelli NJ, Rodriguez-Bigas M, Anderson GR. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J Natl Cancer Inst 1996 Nov;88(22):1665-1670.
- \* 35. Rosenberg L, Kahlenberg M, Vinik AI, Duguid WP. Paracrine/autocrine regulation of pancreatic islet cell proliferation and differentiation in the hamster: studies using parabiosis. Clin Invest Med 1996 Feb;19(1):3-12.
- \* 36. Semelka RC, Schlund JF, Molina PL, Williams AB, Kahlenberg M. Malignant liver lesions: comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. Journal of Magnetic Resonance Imaging 1996;6(1):39-43.

- \* 37. Schlund JF, Semelka RC, Kettritz U, Weeks SM, Kahlenberg M, Cance WG. Correlation of perfusion abnormalities on CTAP and immediate postintravenous gadolinium-enhanced gradient echo MRI. Abdominal Imaging 1996;21(1):49-52.
- \* 38. Rosenberg L, Kahlenberg M, Healey M, Tanguay D. Cyclosporine is detrimental to islet procurement from adult pancreatic tissue. Transplant Proc 1991 Feb;23(1 Pt):767-769.
- 39. Steigelman M, Ortegon D, Wang HT, Kahlenberg MS, Barone CM, Berger J, Daum A. Aesthetic Outcomes in Breast Conservation Therapy (In Press) Aesthetic Surgical Journal

### ***Papers Submitted***

- \* 1. Yi F, Sharkey FE, Prasad SR, Kahlenberg MS. Actinomycotic Infection of the Abdominal Wall Mimicking Malignancy. Surgical Infection (In press)

### **PRESENTATIONS:**

- 10/2006 Management of Gastrointestinal Stromal Tumors, 2nd Annual San Antonio GI Cancer Symposium, Department of Surgery, University of Texas Health Science Center, San Antonio, TX (Keynote Speaker)
- 09/2006 The Multidisciplinary Management of Rectal Cancer., Gastroenterology Grand Rounds, Medicine, University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 06/2006 Colon Cancer Update, The J. Bradley Aust Surgical Society, Thirty-second Annual Meeting 2006, University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 11/2005 The Role of EGFR Inhibition in the Management of Anal Cancer., NSABP Colorectal Cancer Working Group, Baltimore, MD (Sole Presenter)
- 09/2005 Colon Cancer Update; Anal Cancer Update, 1st Annual San Antonio GI Cancer Symposium, Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX (Co-Presenter)
- 08/2005 EGFR tyrosine kinase inhibition increases HER-2 phosphorylation in colon cancer cell lines, Society of Air Force Clinical Surgeons 52nd Annual Symposium, Annual Symposium (Co-Presenter)
- 02/2005 Finding and Treating Cancer in the Breast. The MRI Controversy and Confirming the Value of Sentinel Node Biopsy, Breast Cancer Update 2005, The Alamo Breast Cancer Foundation, San Antonio, TX (Invited Speaker)

- 02/2005 Colorectal Cancer - The Cure Is In the Identification, The Pinion, San Antonio Northwest Rotary Club, San Antonio, TX (Invited Speaker)
- 12/2004 A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma, 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (Co-Presenter)
- 11/2004 HER-2 expression as a predictor of clinical response to neoadjuvant docetaxel in operable breast cancer, 13th Annual Symposium on Cancer Research in San Antonio and South Texas, San Antonio Cancer Institute, San Antonio, TX (Co-Presenter)
- 09/2004 Rectal Cancer: The Need for a Multidisciplinary Approach, Department of Medicine, Division of Gastroenterology & Nutrition, San Antonio, TX (Invited Speaker)
- 05/2004 Multidisciplinary Approach to Rectal Cancer, Medical Oncology Lecture Series/Clinical Case Conference, University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 04/2004 Sentinel Lymph Node Biopsy for Breast Pathology: An Update., Breast Imaging Weekend, American Osteopathic College of Radiology, Chicago, IL (Invited Speaker)
- 04/2004 Breast Cancer Treatment, Breast Imaging Weekend, American Osteopathic College of Radiology, Chicago, IL (Invited Speaker)
- 01/2004 DNA Mismatch Repair Gene Defect of MLH1 and MSH2 in Young Hispanic Patients Under 50 Years with Colon Cancer, 83rd Annual Meeting of the Texas Society of Pathologists (2nd prize winner), Dallas, TX (Co-Presenter)
- 10/2003 The Surgical Approach to Rectal Cancer, Radiation Oncology Grand Rounds, University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 08/2003 Familial Adenomatous Polyposis: Treatment of Colonic and Extracolonic Disease, Grand Rounds, Department of Surgery, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 06/2003 Gastrointestinal Stromal Tumors: A New Treatment Paradigm, J. Bradley Aust Meeting. Cancer Symposium, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 12/2002 Breast Cancer Update, Department of Obstetrics and Gynecology Resident Didactic Conference, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 07/2002 Colorectal Cancer: Awareness, Screening and Treatment Update, American Cancer Society and Texas Medical Association, San Antonio, TX (Sole Presenter)
- 06/2002 Clinical Correlation on the Breast: Medical Gross Anatomy and Embryology, The University of

Texas Health Science Center, San Antonio, TX (Sole Presenter)

- 06/2002 Interpreting Colorectal Operative and Pathology Reports. Nurse/CRA Workshop, Annual Meeting, National Surgical Adjuvant Breast and Bowel Project (Sole Presenter)
- 03/2002 The Surgical Management of Rectal Cancer, Radiation Oncology Grand Rounds, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 02/2002 Receptor Tyrosine Kinases in Colorectal Cancer. Drug Development Lecture Series. Medical Oncology, Medical Oncology, San Antonio, TX (Sole Presenter)
- 02/2002 The Need for Colorectal Cancer Screening, American Cancer Society, San Antonio, TX (Sole Presenter)
- 02/2002 Surgical Management of Rectal Cancer, San Antonio Surgical Society, San Antonio, TX (Sole Presenter)
- 01/2002 The Multimodality Management of Rectal Cancer, General Surgery Grand Rounds, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 11/2001 Breast Cancer Prevention, Diagnosis, and Treatment, 95th Annual Scientific Assembly, Southern Medical Association (Sole Presenter)
- 03/2001 Treatment of Early Colorectal Cancer, Medical Oncology Core Curriculum, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 03/2001 Familial Adenomatous Polyposis: Treatment of Colonic and Extracolonic Disease, South Texas Chapter Annual Meeting, American College of Surgeons (Sole Presenter)
- 03/2001 Cancer Forum Update, American College of Surgeons, South Texas Chapter (Invited Speaker)
- 03/2000 Colorectal Cancer Screening, South Central Texas Society of Gastroenterology Nurses (Sole Presenter)
- 09/1999 Update on Colorectal Cancer, Gastroenterology Grand Rounds, The University of Texas Health Science Center, San Antonio, TX (Sole Presenter)
- 05/1999 Pancreatic neuroendocrine tumors, University Surgical Grand Rounds, University of New York at Buffalo, Buffalo, NY (Sole Presenter)
- 10/1997 Nonsteroidal antiinflammatory drugs (NSAID's) suppress endonuclease expression in colorectal tumor cells, Surgical Forum, American College of Surgeons (Sole Presenter)

10/1996 P53 mutation and genomic instability in sporadic colorectal cancer, Annual meeting of the Western New York Chapter, American College of Surgeons (Sole Presenter)

**RESEARCH GRANTS:**

**Funding Agency:** San Antonio Cancer Institute

**Title:** The Effects of Eugenol on Colorectal Cancer

**Status:** Active

**Period:** 06/2006 - 05/2007

**Role:** Principal Investigator

**Total Costs:** \$15,000.00

**Grant Detail:**

**Funding Agency:** Susan G. Komen Breast Cancer Foundation

**Title:** The Use of Videotapes to Enhance Patient Decision Making in Breast Cancer Treatment

**Status:** Complete

**Period:** 10/2003 - 09/2004

**Role:** Principal Investigator

**Total Costs:** \$8,400.00

**Grant Detail:**

**Funding Agency:** South Texas Health Research Center

**Title:** The Effects of an Aggressive Colorectal Cancer Awareness and Screening Campaign in Bexar County

**Status:** Complete

**Period:** 09/2001 - 09/2003

**Role:** Principal Investigator

**Total Costs:** \$50,000.00

**Grant Detail:**

**Funding Agency:** Howard Hughes Medical Institute

**Title:** Receptor Tyrosine Compensatory Pathways in Response to Her-2-Neu Inhibition

**Status:** Complete

**Period:** 02/2001 - 12/2001

**Role:** Principal Investigator

**Total Costs:** \$10,000.00

**Grant Detail:**

**Funding Agency:** San Antonio Cancer Institute  
**Title:** Compensatory Pathways in Response to Her-2-Neu Inhibition  
**Status:** Complete  
**Period:** 01/2001 - 06/2002  
**Role:** Co-Investigator  
**Total Costs:** \$18,000.00  
**Grant Detail:**

**Funding Agency:** Cancer Center Council, Cancer Therapy and Research Center  
**Title:** Understanding a Novel Mechanism Involved in Colorectal Cancer Development  
**Status:** Complete  
**Period:** 06/2000 - 05/2001  
**Role:** Principal Investigator  
**Total Costs:** \$1,500.00  
**Grant Detail:**

***Federal***

**Funding Agency:** NIH/NCI  
**Title:** Patient Navigator Research Program  
**Status:** Active  
**Period:** 09/2005 - 08/2010  
**Role:** Co-Investigator  
**Total Costs:** \$3,003,791.00  
**Grant Detail:**

**Funding Agency:** NIH  
**Title:** Southwest Oncology Group  
**Status:** Complete  
**Period:** 01/2002 - 03/2004  
**Role:** Principal Investigator  
**Total Costs:** \$41,000.00  
**Grant Detail:**

**Funding Agency:** American College of Surgeons  
**Title:** Cellular Compensatory Pathways in Response to Her-2-Neu Inhibition in Colorectal Cancer: A new Treatment Paradigm

**Status:** Complete  
**Period:** 06/2001 - 06/2003  
**Role:** Principal Investigator  
**Total Costs:** \$80,000.00  
**Grant Detail:**

**Funding Agency:** NIH - (K12)  
**Title:** Her-2-Neu Signal Transduction in Colorectal Cancer  
**Status:** Complete  
**Period:** 07/2000 - 07/2001  
**Role:** Principal Investigator  
**Total Costs:** \$100,000.00  
**Grant Detail:**

**Funding Agency:** NIH - (T32)  
**Title:** Genomic Instability of Colorectal Cancer  
**Status:** Complete  
**Period:** 07/1996 - 06/1998  
**Role:** Principal Investigator  
**Total Costs:** \$50,000.00  
**Grant Detail:**

**Funding Agency:** NIH  
**Title:** National Adjuvant Breast and Bowel Project  
**Status:** Active  
**Period:** / - Present  
**Role:** Co- Investigator  
**Total Costs:** \$415,000.00  
**Grant Detail:**

## **SERVICE**

### **SERVICE TO THE PROFESSION:**

<b><u>Dates</u></b>	<b><u>Type</u></b>	<b><u>Description</u></b>	<b><u>Role</u></b>
12/2006-Present	National	The Breast	Reviewer
12/2006-Present	National	Cancer Research	Reviewer

10/2006-10/2006	National	Symposia	Director
<i>2nd Annual San Antonio GI Cancer Symposium: A Review of the State of the Art and Future Directions in Gastrointestinal Cancer Treatment.</i>			
12/2005-Present	International	Surgery	Reviewer
01/2005-Present	International	The Lancet Oncology	Reviewer
08/2004-Present	International	Annals of Surgical Oncology	Editorial Board Member
08/2004-Present	International	International Journal of Cancer	Reviewer
01/2004-Present	International	Cancer Research	Reviewer
01/2004-Present	International	Clinical Cancer Research	Reviewer
01/2003-Present	International	Investigational New Drugs (journal)	Reviewer
01/2002-Present	International	American Society of Clinical Oncology	Member
01/2002-Present	International	Journal of Clinical Oncology	Editorial Board Member
01/2002-Present	International	International Journal of Gastrointestinal Cancer	Editorial Board Member
01/2002-Present	National	ASCO Membership Committee	Member
01/2001-01/2001	National	Cancer Symposium, American College of Surgeons South Texas Annual Meeting	Guest Lecturer
01/2001-Present	National	Southwest Oncology Group (SWOG)	Member
<i>Surgical Liaison GI Committee and GI Committee Working Group</i>			
01/2001-Present	National	National Surgical Adjuvant Breast and Bowel Project (NSABP)	Member
<i>Colorectal Committee and Colorectal Working Group Committee (Limited to 25 members)</i>			
01/2001-Present	National	Annals of Surgical Oncology	Reviewer
01/2001-Present	National	Journal of Surgical Oncology	Reviewer

01/1999-Present	National	Cancer	Reviewer
-----------------	----------	--------	----------

**SERVICE TO THE PUBLIC:**

<b><u>Dates</u></b>	<b><u>Type</u></b>	<b><u>Description</u></b>	<b><u>Role</u></b>
04/2002-04/2004	Community	Colorectal Cancer: Awareness, Screening and Treatment Update. Statewide Meeting for American Cancer Society and Physicians Oncology Education Program	Chair
06/2000-05/2005	Community	Cancer Prevention. Surgical Oncology Cancer Prevention Programs, UTHSCSA.	Director
05/2000-05/2005	Community	American Cancer Society/Colorectal Cancer Task Force Committee	Chair
02/2000-02/2002	Community	American Cancer Society	Board of Directors

**PROFESSIONAL AFFILIATIONS:**

<b><u>Dates</u></b>	<b><u>Organization</u></b>
02/2005-Present	Society of University Surgeons
<i>Additional Details: Represents nationally recognized academic achievement in surgery. Limited to 250 members.</i>	
09/2001-Present	Association for Academic Surgery - Member
01/2001-Present	American College of Surgeons - Fellow
05/1999-Present	The American Society of Clinical Oncology - Member
04/1996-Present	The American Association for Cancer Research - Member
03/1996-Present	The Society of Surgical Oncology - Member

**COMMITTEES:**

<b><u>Dates</u></b>	<b><u>Committee</u></b>	<b><u>Role</u></b>
03/2007-Present	National Cancer Institute's Neuroendocrine Tumor Task Force	Member
03/2007-Present	Society of Surgical Oncology Training Committee	Member
01/2006-Present	Regional Community Advisory Committee (RCAC), Redes en Accion,	Member

University of Texas, School of Public Health, Center for Health Promotion  
and Prevention Research

08/2005-Present	San Antonio Cancer Institute Executive Committee	Member
06/2005-Present	NSABP Foundation Research Program (FRP) Steering Committee, National Surgical Breast and Bowel Project (NSABP)	Member
03/2005-Present	San Antonio Cancer Institute - Geriatrics Program	Member
03/2005-Present	San Antonio Cancer Institute Cancer Prevention Program	Member
01/2003-Present	San Antonio Cancer Institute- Clinical Oncology Research Committee, San Antonio Cancer Institute	Member
01/2001-Present	CTRC - Ambulatory Surgery Center Medical Executive Committee, Cancer Therapy & Research Center	Member
01/2001-Present	CTRC - Ambulatory Surgery Center Governing Board, Cancer Therapy & Research Center	Chair
01/2001-Present	Colorectal Cancer Working Group Committee, NSABP	Member
01/1999-03/2004	San Antonio Cancer Institute – Prostate Cancer Program, Cancer Therapy & Research Center	Member
01/1999-Present	San Antonio Cancer Institute – Gastrointestinal Cancer Program, San Antonio Cancer Institute	Member
01/1999-Present	San Antonio Cancer Institute – Developing Program Committee, San Antonio Cancer Institute	Member

---